Summer can be one of the toughest times to be single. There’s nothing worse than looking at Instagram or Facebook and seeing your married/couple friends off on vacation in the South of France or spending the weekend at a BBQ in the Hamptons while you stare longingly at your dog in your cramped apartment wishing your fire escape could morph into the Caribbean Sea or a gondola in Venice. If you haven’t met Mr. or Ms. Right by Memorial Day Weekend how can you salvage your summer? Dr. Sanam Hafeez is an NYC Neuropsychologist who also happens to be a single mom of two boys. This is no trivial matter. Loneliness can literally be a killer! It can lead to depression, substance abuse, suicidal thoughts, and other destructive behaviors. Here she shares some ideas to socialize without a significant other during the dog days of summer.
Take A Daycation
There is something called www.resortpass.com. While this is not yet available in every city, it does allow people to book day passes at luxury hotels and use their beach, pool, spa, and amenity facilities in some cases for as little as $25.00 per day! Hotels such as Kimpton, W, Westin, Hyatt, Ritz Carlton, St. Regis and many others offer this. Not only does soaking up Vitamin D makes us feel good, who knows, your lounge mate could turn into an evening date!
Try a Meet Up
Meetup is about connecting people with something in common. From activities you love and hobbies you want to try, to ways you identify yourself and who you want to be, a Meetup group is a community. A community of people who come together because they care about the same thing. Mountain climbers, first-time parents, aspiring kite surfers, chefs, coders… you name it, there’s a good chance there’s a Meetup group for it. You can join online or through the app and find a Meet Up group that fits your exact interest.
Don’t Let Being Single Ground You or De-Rail Your Travel
Let’s face it, unless you are an extraordinarily confident and independent person, it can be unsettling to travel solo to a foreign country and eat meals alone and wander around with nobody to converse with. This need not be the case! There are many travel groups that build their business around single travelers who are more mature than Club Med. Once such company is https://www.singlestravelintl.com Their vacations run the gamut from weekends, cruises, adventure travel, and international travel. And they are just one of many companies who do this.
For the Single Person in Recovery From Drugs or Alcohol
Very often, “Singles Vacations” can mean party time and this can be challenging for those in recovery. There are hundreds of thousands of people who fall into this category, and that’s why sober vacations exist. https://sobervacations.com is one company that has been around since 1987, however numerous others exist.
Summer Camp for Adults
If you were lucky enough to go to summer camp as a kid, doesn’t that bring back great memories of camp fires and roasting smores? You can recreate that experience in a co-ed environment! Adult summer camps are a “thing” and they are popping up all over the country. www.campbonfire.com is an example where the activities are so varied and sundry from rock climbing, pool parties, Thai massage, kickball, survival skills, or doing nothing at all!
Volunteer
What do you like? Pets? Art? Kids? Try any place where they can be found, like a shelter, museum or hospital. It really gives you a boost to give unconditionally.
Find an Extra Job Doing Something You Really Enjoy
Only do so if it won’t add unwanted stress to your life.Look up freelance opportunities in your area doing what you're skilled at. The extra income will make you feel better and give you more cash to spoil yourself.
Swap Your Home/Apt With a Friend Temporarily
It beats the cost of a hotel and can certainly get you out of a rut and in front of new people! Perhaps, you’re a woman living in New York and are not feeling it with the men in the big apple. Maybe you have a friend in LA you can swap homes with to see how you vibe with the pace and the people on the west coast. It gives you a chance to feel things out without making a long-term commitment.
“The bottom line,” says Dr. Hafeez, “is that with some well thought out planning, you need not be single and lonely during the summer months. You can fill your time with people, sun, fun, adventures, new cultures, and in the process of doing so, you just might find “the one.”
Modernized Canadian Strategy for Cancer Control Released
Over 7,500 Canadians includinghealthcare partners informed five priorities to improve cancer care in the next decade
TORONTO, June 4, 2019 /CNW/ -The Canadian Partnership Against Cancer (the Partnership) has released the modernized Canadian Strategy for Cancer Control. The Strategy is a 10-year roadmap to deliver world-class cancer care to all Canadians, families and caregivers affected by the disease. The Strategydetails actions that will improve equity of access to high-quality care, and actions to ensure we have a sustainable healthcare system for the future.
The priorities of the refreshed Strategy will build on advancements in cancer control. The Partnership's CEO Cynthia Morton says the Strategy provides a bold vision, "We can see that the ability to deliver specialized cancer care virtually with localized supports and caregivers is improving access to care in rural and remote communities. HPV vaccinations will continue to help in the push to eliminate cervical and other related cancers. And genomics, targeted therapies and immunotherapy are now creating treatment options for cancers that were once untreatable." Morton also notes the leadership of the Partnership in helping to spread these changes across the cancer system, "Our organization is proud to act as a pan-Canadian convenor and steward of the Strategy and we will work with our many partners to deliver real change through its implementation, and will keep Canadians informed on our collective progress."
The original Strategy was developed in 2006. The cancer landscape in Canada and across the world has changed considerably, creating new opportunities and challenges. To address this, the Partnership led efforts to modernize the Strategythrough extensive engagements gathering input from over 7,500 Canadians including cancer patients, health care providers, policy makers and many others in the cancer community. The Partnership also engaged First Nations, Inuit and Métis communities, governments and organizations about Peoples-specific priorities in cancer care.
The Partnership is the steward of the Strategy and works with those on the front lines in all provinces and territories – cancer agencies, healthcare professionals, not-for-profit organizations, people with cancer, and those who care for them – to address challenges requiring new solutions and pan-Canadian action. TheStrategy's five priorities will tackle the most pressing challenges for the next decade:
Decreasing the risk of people getting cancer
Diagnosing cancer faster, accurately and at an earlier stage
Delivering high-quality care in a sustainable, world class system
Eliminating barriers to people getting the care they need
Delivering information and supports for people living with cancer, families and caregivers
First Nations, Inuit, and Métis communities, governments and organizations were engaged across Canada. Three additional priorities are reflected in the refreshed Strategy which are viewed as vital in decreasing the risk of getting cancer, and seeing equitable access to quality care, for Indigenous peoples in this country. Each priority has Peoples-specific actions to help drive the changes needed. These include:
Culturally appropriate care closer to home
Peoples-specific, self-determined cancer care
First Nations-, Inuit- or Métis-governed research and data systems
Continued engagement by the Partnership and partners in the cancer system with First Nations, Inuit and Métis communities, governments and organizations is critical to developing self-determined, Peoples-specific implementation plans across Canada.
Additional Quotes
"The refresh of the Strategy identifies what the First Nations, Inuit and Métis nations have articulated as priorities for the delivery of cancer care and the required supports needed to action these priorities in their respective communities. Our Métis community here in Manitoba looks forward to working alongside the Partnership to improve our cancer services in the coming years."
-Cheryl Smith is the Reeve (Mayor) of the Rural Municipality of St. Laurent, Manitoba. The community of St. Laurent is the largest Métis community in Canada. She is also the Indigenous Board Member of the Canadian Partnership Against Cancer
"The Government of Canada is committed to supporting Canadians living with cancer and their families who are affected by this disease. I want to thank the Partnership for their efforts in leading on the development of the refreshed Strategy and the Canadians who participated in the consultations. Your input was invaluable to its development and its implementation in the future."
-The Honourable Ginette Petitpas Taylor Minister of Health
"We know a cancer diagnosis can change everything, which is why this bold Strategy to reduce the burden of cancer in Canada is critically important. Nearly 1 in 2 Canadians is expected to be diagnosed with cancer in their lifetime and, at the same time, more people are surviving their diagnosis than ever before. By working collectively with health care partners and stewards like the Partnership and supporting the priorities of the new Strategy, we can improve the cancer experience, helping people live longer and enhancing their quality of life."
-Andrea Seale Interim CEO of the Canadian Cancer Society and upcoming Board Member of the Canadian Partnership Against Cancer
Next Steps The Strategy was presented to the federal Minister of Health, her Ministry colleagues and all members of Parliament. This is Canada's cancer strategy, built by Canadians from coast to coast to coast. Beginning immediately and running through fall 2019, the Partnership will meet with key stakeholders including provincial and territorial governments, Indigenous partners, patient groups and cancer organizations to discuss the Strategy's priorities and implementation plans. No single organization has the resources or ability to implement the Strategy by itself, and success will require an active commitment by the entire cancer community, working together, to deliver results. Implementation plans will be developed over the coming months through innovative partnerships with clear and measurable work plans.
Pan-Canadian Engagement The engagement process used in developing the refreshed Strategy proactively invited input from a large and diverse group of Canadians and cancer control partners in all provinces and territories. Thousands of Canadians provided input through an online survey, in-person sessions and written submissions. Participants included patients and caregivers, the general public, health system and cancer community leaders and people who are underserviced by the health system such as recent immigrants, people who identify as LGBTQ2, minority language communities and rural, remote and northern residents. An engagement process with First Nations, Inuit and Métis Elders, advisors, governments, organizations, and communities across Canada also informed the Strategy's priorities, and a panel of external experts and international changemakers assisted the Partnership throughout the process.
About the Canadian Partnership Against Cancer As the steward of the Canadian Strategy for Cancer Control (the Strategy), the Partnership works with Canada's cancer community to take action to ensure fewer people get cancer, more people survive cancer and those living with the disease have a better quality of life. This work is guided by the Strategy, which was refreshed for 2019 to 2029 and will help drive measurable change for all Canadians affected by cancer. The Strategy includes five priorities which will tackle the most pressing challenges in cancer control as well as distinct First Nations, Inuit and Métis Peoples-specific priorities and actions reflecting Canada's commitment to reconciliation. The Partnership will oversee the implementation of the priorities in collaboration with organizations and individuals on the front lines of cancer care – the provinces and territories, health-care professionals, people living with cancer and those who care for them, First Nations, Inuit and Métis communities, governments and organizations, and its funder Health Canada. Learn more about the Partnership and the refreshed Strategy at www.cancerstrategy.ca.
SOURCE Canadian Partnership Against Cancer
For further information:
Nick Williams, Communications Officer, Media Relations, Canadian Partnership Against Cancer, 416-915-9222, x5799 (office), 647-388-9647 (mobile), nick.williams@partnershipagainstcancer.ca
Many Canadian Adults Acknowledge the Importance of Immunization Yet Are Not Getting Vaccinated
Survey finds that although 82% of Canadian adults agree that staying up to date with vaccinations is important, one in four (27%) admit it isn't a priority to them.
MISSISSAUGA, ON, June 4, 2019 /CNW/ - While most Canadian adults recognize the importance of vaccinations, when it comes to their own health, not everyone is vigilant in seeking to protect themselves against vaccine-preventable diseases. In fact, according to a recent Ipsos survey commissioned by GSK, while the majority (82%) of Canadian adults agree that staying up to date with vaccinations appropriate for them is important, more than one in four (27%) say doing so simply isn't a priority.1
"Given the many competing health priorities to cover during healthcare visits, it's essential for Canadians to not lose sight of the importance of immunization throughout life," said Dr. Alex Romanovschi, Country Medical Director, GSK Canada. "Like regular exercise and a healthy diet, vaccines are an important tool to consider when thinking about overall health and wellness."
Vaccines Are Not Something You Outgrow Immunization is often top of mind for new and expecting parents as vaccination in childhood has become well engrained in society today. In Canada, children are vaccinated early at various stages and often vaccines need to be given as a series of doses.2
According to the survey, slightly more than six in ten (63%) Canadian adults describe themselves as knowledgeable about childhood vaccinations.
Adult Vaccination Knowledge and Views For adults, keeping up to date on recommended vaccines into adulthood is also important. As we age, our immune system gradually weakens and becomes less effective at protecting us from disease, increasing the chances of catching infections.
Despite 93% of Canadian parents agreeing that they have a responsibility to their family to ensure they take care of their own health, roughly half (52%) feel that keeping up to date on adult vaccinations is less important than making sure their child or children are up to date on recommended childhood immunizations.1
"It's important to know that some vaccines you receive as a child can wear-off over time and teenagers and adults may need to receive a booster vaccination," noted Dr. Romanovschi. "Further, in some cases there are diseases that most commonly occur at an older age that some people may not realize could potentially be prevented by vaccination."
Learn About Which Vaccines May be Right for You It can be difficult to know which vaccines may be important for you and at what age. Some vaccines are publicly funded while others may need to be purchased, with each province varying. According to the survey, Canadians are less aware of which vaccines they may need beyond those provided through public immunization programs, with just over half (56%) believing that all vaccines that are important for them are provided for free through their province's public health programs.1
Healthcare providers have an important role to play in helping Canadian adults prioritize their own health as more than eight in ten Canadians (84%) say they would turn to their doctor or primary care provider for advice on vaccinations in adulthood. However, in the past 12 months, only three in ten (29%) have asked their doctor or another healthcare professional for advice on adult vaccines.
"By better understanding the importance of immunization throughout life, Canadians can then consider making it a priority to discuss with their healthcare providers which vaccines may be right for them at what age," said Dr. Romanovschi.
About the Study These are some of the findings of an Ipsos survey conducted between March 4 and March 7, 2019, on behalf of GSK. For this survey, a random sample of 1,802 Canadians aged 18+ were interviewed online via the Ipsos I-Say panel. Weighting was then employed to balance demographics to ensure that the sample's composition reflects that of the adult population according to Census data and to provide results intended to approximate the sample universe. The precision of Ipsos online surveys is measured using a credibility interval. In this case, the survey is accurate to within ±2.6 percentage points, 19 times out of 20, had all Canadian adults been polled. The credibility interval will be wider among subsets of the population. All sample surveys and polls may be subject to other sources of error, including, but not limited to coverage error, and measurement error.
GlaxoSmithKline (GSK) GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We are the global leader in vaccines – developing, producing and distributing a broad portfolio of paediatric, adolescent, adult and travel vaccines. For further information, please visit www.ca.gsk.com.
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
EDMONTON, June 4, 2019 /CNW/ - Boehringer Ingelheim (Canada) Ltd., the University Hospital Foundation and the Government of Alberta are pleased to announce a collaboration which will focus on developing solutions to address treatment gaps in the area of Chronic Obstructive Pulmonary Disease (COPD) care and its associated co-morbidities.
The Alberta Boehringer Ingelheim Collaboration (ABIC) is a public-private philanthropic partnership developed to support innovation and industry-driven, applied research in Alberta's life science sector. The ultimate goal is to advance health innovation projects in the area of respiratory diseases, in particular COPD and its associated co-morbidities including diabetes, obesity and heart failure.
The partnership will be announced later today on the Canadian Pavilion Stage at the BIO International Convention in Philadelphia, PA. The BIO International Convention brings together more than 16,000 attendees from around the globe for unparalleled collaboration amongst key partners in the biotech industry.
Purpose of the Alberta Boehringer Ingelheim Collaborative Partnership Fund (ABIC)
In partnership with Boehringer Ingelheim (Canada) Ltd., the University Hospital Foundation and the Government of Alberta, the Collaborative is inviting proposals from Alberta-based investigators for funding to help identify, develop and implement effective solutions from early diagnosis to end-of-life in people with respiratory diseases. Projects that are submitted must address one of the three healthcare gaps identified below:
Early Diagnosis and Coordinated Screening: 50% or more of COPD patients in Alberta remain undiagnosed
Patient Awareness and Education related to COPD: Lack of disease self-management programs
Connecting Patients to Services: Connecting patients to available and appropriate services for COPD patients
"We are pleased to announce our collaboration with the Government of Alberta and the University Hospital Foundation to advance innovation in healthcare" said Uli Brödl, Vice President, Medical and Regulatory Affairs, Boehringer Ingelheim (Canada) Ltd. "Patients are at the heart of everything we do, and we are dedicated to developing novel solutions that drive transformative change for a better patient experience."
Alberta is uniquely positioned for these partnerships because of the strength of its life sciences sector, the proven willingness of many organizations to partner with a common vision, and the provincial government's commitment to increasing economic diversification, by building Alberta's knowledge economy.
"Through public-private philanthropic partnerships like this, we are able to pioneer innovative solutions that will reduce costs, support a sustainable healthcare system and improve access to care for patients," says Christy Holtby, Vice President, Strategic Partnerships with the University Hospital Foundation. "We're so grateful for the support from community members through our Foundation to help fund this forward-thinking collaboration."
Through this partnership between Boehringer Ingelheim (Canada) Ltd., the Government of Alberta and the University Hospital Foundation, the power of collaboration between industry, the public and philanthropic sectors are brought together with the shared vision of translating goals into real-world practice. Together, the collaboration will uncover evidence that will allow the organizations to make major changes in how they battle these chronic diseases and enable Canadians to live better lives.
University Hospital Foundation The University Hospital Foundation raises and manages funds to advance patient care, research and healthcare education at the University of Alberta Hospital, the Mazankowski Alberta Heart Institute and the Kaye Edmonton Clinic. Through Strategic Partnerships, the University Hospital Foundation brings together industry, the public sector, and philanthropic collaborations to advance and translate Alberta's innovations into solutions that impact the health of all Albertans. With this collaborative approach to invest in shared areas of interest, the Foundation's philanthropic investment – and that of our partners - is multiplied. www.GivetoUHF.ca
Government of Alberta The Ministry of Alberta Economic Development, Trade and Tourism focuses on economic growth and diversification by supporting innovation and research; expanding access to capital for small and medium-sized enterprises; promoting trade, investment and market access initiatives; and leading Alberta's negotiations on trade agreements. http://economic.alberta.ca
Boehringer Ingelheim (Canada) Ltd. Improving the health of humans and animals is the goal of Boehringer Ingelheim, a research-driven pharmaceutical company. In doing so, the focus is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients' lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 50,000 employees create value through innovation daily for the three business areas of human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
TORONTO, June 4, 2019 /CNW/ - A new survey commissioned by Alcon Canada, revealed that over half of Canadians do not know much about cataracts and cataract surgery; and 59 per cent are unaware that there are options to treat cataracts and other vision conditions at once1. This is particularly concerning as cataracts affect 2.5 million Canadians every year2 and are one of the leading causes of blindness and low vision in age-related eye diseases3.
With National Cataract Awareness Month happening this June, Alcon is emphasizing the importance of regular eye exams and awareness of cataracts, as part of their ongoing See the Full Picture campaign.
"Our eyes are our windows to the world and no two are the same," says Dr. Kathy Cao, a Toronto-based ophthalmologist with the Kensington Eye Institute. "It's so important that everyone is proactive about their eye health, visiting an eye care professional every year to protect their sight, especially if there are changes in their vision."
As people age, their eyes change and different natural eye conditions may develop. Two of the most common aging eye conditions are presbyopia and cataracts. Presbyopia is a gradual loss in the eye's ability to pull the lens into shape affecting our ability to focus on close objects.
A cataract is the clouding of the lens in your eye, caused from protein build up over time. For people who have cataracts, vision becomes increasingly blurry, making it difficult to see4.
Vision loss can affect a patient's ability to perform simple daily tasks and it diminishes the beauty that life has to offer through one's vision. Colours become muted, expressions on loved one's faces become difficult to see and activities like reading and driving become nearly impossible. It's as if you are seeing everything through a cloud or fog.
The survey, conducted by Leger, The Research Intelligence Group, was designed to examine the perceptions of and awareness of cataracts and vision health among Canadians between the ages of 55-79. It revealed that seeing clearly is incredibly important to Canadians -- 75 per cent prioritize clearly seeing the faces of loved ones, 69 per cent want to have the ability to see details and colours more clearly, and 66 per cent want to feel more confident when travelling the world as the top reasons for wanting clear vision1.
Yet, the majority of people surveyed spend very little time thinking about their vision and for those who have cataracts, 50 per cent say that fear is a barrier to seeking treatment1.
"We often hear from patients that they are worried or nervous about cataract surgery," says Dr. Cao. "While every surgery should be carefully considered, cataract surgery is generally safe and done on an outpatient basis, which means patients go home the same day after surgery, and often start to notice vision improvements within a couple of days and may return to regular life activities shortly after."
Before having cataract surgery, it's important that patients have informed discussions with your surgeon about your vision goals. There are a variety of different lens replacement options used during cataract surgery that can treat multiple eye conditions at once. Choosing the lens for your goals could mean seeing the world in vivid colour or not having to wear reading glasses.
For years, cataract replacement lens options were limited. Now patients have the option of trifocal lenses that provide superior vison at multiple distances allowing patients to see everything near, far and in-between. For many patients frustrated with constantly searching for reading glasses to read the paper or their phone, the opportunity to become glasses free is a huge advantage.
"I've always loved shape and colour and texture and I hadn't realized how much I was missing," says Tracey Dorey, patient and retired teacher. "Over the last few years, my vision had deteriorated to the point where I was living in a narrow world of muted colour. Since my surgery, my whole outlook about who I am and what I can do has changed. I feel like a whole new person – it's been such a big turning point in my life."
To learn more about cataracts, cataract surgery and lens options, visit your eye care professional to receive a comprehensive eye exam and visit SeeTheFullPicture.ca. To help guide the discussion with your eye care professional, download a discussion guide here.
Survey Methodology
Leger, The Research Intelligence Group, surveyed 1503 Canadians, aged 55-79, between November 8 and November 18, 2018 using Leger's online panel, LegerWeb. A probability sample of the same size would yield a margin of error +/- 2.5%, 19 times out of 20. Leger's online panel has approximately 400,000 members nationally with a retention rate of 90%. Panel members were randomly selected to receive an email invitation to the survey.
About Cataracts
A cataract is a cloudy area in the natural lens of the eye that affects vision. As a cataract develops, the eye's lens gradually becomes hard and cloudy allowing less light to pass through, which makes it more difficult to see. The vast majority of cataracts happen as a result of normal aging but radiation exposure, taking steroids, diabetes, and eye trauma can accelerate the development of cataracts. Cataracts are the most common age-related eye condition and the leading cause of preventable blindness4. Currently, more than 2.5 million people in Canada have cataracts2. Cataracts are treated by removing the eye's cloudy natural lens and surgically replacing it with an intraocular lens or IOL. More than 98 per cent of cataract surgeries are considered successful and patients typically can return to their normal routines within 24 hours4.
About Astigmatism and Presbyopia
Astigmatism is a variation in the shape or curvature of the cornea and, if left untreated, can cause blurred vision at all distances. Presbyopia is an eye condition that occurs as part of natural aging. It involves the gradual loss of the eye's ability to actively focus on close objects, such as smart phones, computers, books and menus. The first signs of presbyopia are eyestrain, difficulty seeing in dim light and problems focusing on small objects and/or fine print. Once a person is in their 40s, it is likely they will experience presbyopia and will require vision correction such as reading glasses or multifocal contact lenses.
About Alcon
Alcon is the global leader in eye care, provides innovative products that enhance quality of life by helping people see brilliantly. Alcon Surgical and Vision Care business franchises offer the widest spectrum of eye care products in the world. Headquartered in Fort Worth, Texas, USA, Alcon has operations in 75 countries and products available in 180 markets. For more information, visit www.alcon.ca.
______________________________________ 1Cataract Awareness Survey, 2018. This survey was conducted online by Leger, The Research Intelligence Group, on behalf of Alcon Vison Care from November 8 until November 18, 2018, among 1,503 Canadians age 55 through 79, using Leger's online panel LegerWeb. A probability sample of the same size would yield a margin of error +/- 2.5%, 19 times out of 20 2 Canadian Journal of Ophthalmology. Distribution Gaps in Cataract Surgery Care and Impact on Seniors Across Ontario. Accessed January 2019. Available at: https://www.sciencedirect.com/science/article/pii/S0008418218306215 3 Centers for Disease Control and Prevention. Common Eye Disorders. Accessed September 2015. Available at: https://www.cdc.gov/visionhealth/basics/ced/index.html 4 Cleveland Clinic. Cataracts. Accessed August 2015. Available at: http://my.clevelandclinic.org/services/cole-eye/diseases-conditions/hic-cataracts
SOURCE Alcon Canada
WUNDABAR PILATES LAUNCHES HIGHLY ANTICIPATED ON-DEMAND SERVICE
Founder, Amy Jordan, Develops Programming That Translates In-Studio Experience Into 30-Minute Streaming Workouts
Los Angeles, Calif. (June 4, 2019) – WundaBar Pilates, the bi-coastal leading chain of elevated Pilates studios, is expanding its audience reach with the launch of WundaBar Pilates On-Demand. The streaming service translates the in-studio experience on the WundaFormer, the revolutionary, patented reformer machine available exclusively to WundaBar Pilates, to 30-minute workout videos available online to a global audience.
Founder, Inventor and Chief Executive Officer of WundaBar Pilates, Amy Jordan, meticulously mapped out the WundaBar Pilates On-Demand programming to parallel the in-studio experience, complete with wellness programs, calendars, motivation worksheets and more. “WundaBar Pilates was created to strengthen, empower and support a community of like-minded individuals that strive to better their health and wellness both physically and mentally,” stated Jordan. “Before WundaBar Pilates On-Demand, the only way to reach our audience was through one of our studios, but now we can expand our community wider and deeper through connection. I am thrilled to be able to offer that feeling to whoever joins us.”
WundaBar Pilates On-Demand launches with two initial packages, “2 Weeks 2 Wunda” and “6 Weeks 2 Wunda.” Each package will provide dedicated offerings and programming that boast proven results in as little as two weeks. To access WundaBar Pilates On-Demand, please follow this link: https://www.wundabar.com/wundabar-pilates-on-demand
The available programming outlines include:
2 WEEKS 2 WUNDA ($29.99) – A Two-Week, Intensive Program for Immediate Results
Quick Start Guide - everything you need to hit the ground running!
Workout Videos - two new booty-kicking workouts to add to your rotation.
Wunda Workout Calendar - no guesswork, just workout!
Exclusive Members-only Facebook Group - you belong! Let's succeed together!
Food Is Fuel Approach - your no-nonsense guide to fuel up and slim down.
6 WEEKS 2 WUNDA ($79.00) – A Six-Week, Results-Driven Program for Immediate and On-Going Success
Quick Start Guide - your plan to succeed!
Workout Videos - six more killer workouts to add to your stash.
Wunda Workout Calendar - your schedule, simplified.
Unbreakable Motivation Worksheet - the key to keeping you going!
Food Is Fuel Approach - no nonsense, just real food.
WundaBar Pilates On Demand Facebook Group - connect and succeed together!
Amy's Pro Tip Emails - 7 weekly videos with tips to help you up-level your form and your results!
Bonus Videos
10 Minute Red Hot Band Workout - short on time, long on results.
WundaShake with Amy Jordan - shake up the most important meal of the day.
Nutrition Restart Kim Shapira - change your relationship with food in three simple steps.
Unbreakable Motivation Coaching with Kate Simmons - live your Vision Fulfilled today.
1-Min Morning Meditation with Kate Simmons - start your day off with this 1-minute practice.
Vision Meditation with Kate Simmons - train your brain and the body will follow.
WundaBar Pilates has seen massive expansion since its founding in 2011. Amy Jordan continues to innovate and push the boundaries of the fitness industry through her determination and perseverance by creating a worldwide, connected wellness community with the launch of On-Demand. WundaBar Pilates has eight locations nationwide including two recently renovated studios in Studio City and Pasadena. Summer 2019 marks the opening of its ninth location in New York City’s Upper East Side.
Please feel free to reach out if interested in utilizing WundaBar founder Amy Jordan as an expert or to create custom workouts for your readers.
ABOUT WUNDABAR:
Established in 2011 by Pilates visionary, entrepreneur and inventor, Amy Jordan, The WundaBar Approach combines beautiful biomechanics and traditional Pilates with efficient movement, exceptional flow and a cardio-intense pace. The patented WundaFormer – a Pilates Reformer, WundaChair, Jumpboard and Ballet Bar all-in-one - brings four powerful apparatuses into reach for a wide audience and into the group class environment where previously, they had no practical application as separate pieces of equipment. WundaBar Pilates has eight bi-coastal locations, two recently renovated studios, Studio City and Pasadena, as well as a Summer 2019 opening of its ninth location in New York City’s, Upper East Side. https://www.wundabar.com/
Nanostics Announces Launch of its Clinical Validation Study for ClarityDX Prostate
EDMONTON, June 4, 2019 /CNW/ - Nanostics Inc., a company developing a novel liquid biopsy platform for the early diagnosis of clinically significant prostate cancer, is pleased to announce the start of its key clinical validation study. The study will be carried out with blood to be sampled from 2,800 men with elevated PSA levels. Patient recruitment will be managed by the Alberta Prostate Cancer Research Initiative (APCaRI) and will start in Alberta at Calgary's Prostate Cancer Centre (PCC) and Edmonton's Northern Alberta Urology Centre (NAUC). Recruitment of men from the Yukon Territories will follow.
Previously, a 415-patient prospective clinical study established the validity of this novel liquid biopsy platform and determined it to be 40% more specific than the standard prostate cancer blood screen test, PSA. Nanostics also very recently completed an intensive 2,000 sample stability study with the liquid biopsy blood test to determine the optimal collection and transportation conditions.
This new clinical validation study is part of the process towards meeting FDA and Health Canada requirements for an in vitro diagnostic test, which will allow Nanostics proprietary ClarityDX Prostate test to be provided to patients. The study will be conducted in partnership with DynaLIFE Medical Labs, an award-winning company which provides clinical services for over 2 million patients in its facility in Edmonton, as well as APCaRI at the University of Alberta. The co-principal investigators of this study are Dr. Eric Hyndman (PCC) and Dr. Adrian Fairey (NAUC), both notable urologists and prostate cancer researchers. Funding for the clinical study comes in part from the Motorcycle Ride for Dad, Alberta Cancer Foundation, Alberta Innovates-ASBIRI program and the University Hospital Foundation Kaye Fund.
"We are extremely excited to be moving to the next phase of clinically validating the ClarityDX Prostate test", John Lewis, CEO of Nanostics said, "and we are grateful to all the support we have received here in Alberta to make this possible."
The potential impact of the ClarityDX Prostate test is considerable; implementation could eliminate up to 600,000 unnecessary biopsies, 24,000 hospitalizations and up to 50% of unnecessary treatments for prostate cancer in North America. Beyond an estimated cost savings to the healthcare system of more than $1.4B per year, this will have a dramatic impact on the healthcare experience and quality of life for men.
"DynaLIFE is committed to working with innovative technologies that can improve the health outcomes of Albertans" said Jason Pincock, CEO of DynaLIFE Medical Labs, "we are excited to see the results that will come out of the ClarityDX Prostate clinical study and to be working with Nanostics to help improve the diagnosis of prostate cancer."
About Nanostics Inc. Nanostics is a privately held company focused on the development and commercialization of novel and non-invasive diagnostic tests. Our core technology can diagnose disease from a simple blood test by combining a highly sensitive extracellular vesicle (EV) detection platform with advanced machine learning algorithms. Our novel technology is applicable to a wide range of cancers and other diseases. Our lead product, ClarityDX Prostate, is set to become the first clinically validated test using this exciting new EV detection technology.
About DynaLIFE Medical Labs DynaLIFE Medical Labs provides diagnostic laboratory services to more than 2,000 physicians and two million patients annually. The laboratory, locally managed from its state-of-the-art facility in Edmonton, performs more than 14 million tests every year. The laboratory employs the newest technologies to ensure that patients receive the best possible laboratory services.
SOURCE Nanostics
$2.4M to support cancer research projects in Quebec - Announcement of the IRICoR and Oncopole LeadAction-Onco Competition winners
MONTREAL, June 4, 2019 /CNW Telbec/ - IRICoR and the Oncopole are proud to announce, as part of the LeadAction-Onco joint project, an investment of $2.4 million dollars over two years, to support four flagship cancer drug discovery projects in Canada. This major announcement was made today by Mr. Pierre Fitzgibbon, Minister of Economy and Innovation, on the occasion of the opening of the Quebec Pavilion at the BIO International Convention, held in Philadelphia June 3-6, 2019.
The funding for the Competition is the result of a collaboration with leading financiers, namely the Ministry of Economy and Innovation and the federal government through IRICoR, as well as Merck and the FRQS through the Oncopole. This major funding will enable the selected projects to benefit from infrastructures, as well as from targeted and complementary expertise in the field of drug discovery.
"The LeadAction-Onco competition is an exceptional opportunity to support creative projects that ensure the development of new treatments for people with cancer. This competition also helps Québec attract foreign investments that generate significant spin-offs for our life sciences industry," Pierre Fitzgibbon, Minister of Economy and Innovation, stressed.
"This initiative will improve the transition between the innovation and commercialization phases by bridging the gaps between the academic, pharmaceutical and industrial milieus, ensuring that our digital economy will benefit everybody" added the Honourable Navdeep Singh Bains, Minister of Innovation, Science and Economic Development.
The LeadAction-Onco Competition
The LeadAction-Onco Competition led by IRICoR and the Oncopole is an opportunity for Canadian researchers to greatly accelerate the transformation of their projects in oncology, for the benefit of patients.
"IRICoR is delighted by the remarkable quality of the projects submitted as part of the LeadAction-Onco Competition launched in Quebec and throughout the rest of Canada. In concert with the Oncopole, the universities and the institutions involved, IRICoR will closely support the winning teams in order to develop their projects in such a way as to establish co-development partnerships with industry or to create spinoff companies, as has successfully been done in the past. Applying the IRICoR model to these projects, with respect to funding as well as drug discovery and business expertise, will undoubtedly lead to innovative therapeutic solutions", added Nadine Beauger, Chief Executive Officer, IRICoR.
"The Oncopole aims to consolidate the Quebec cancer research ecosystem and to highlight discoveries, in order to maximize clinical practices. The LeadAction-Onco Competition fits perfectly into this innovative approach and is proof of a very productive synergy with the various players in the field of life sciences, such as IRICoR. This investment enables the Oncopole to energize the transfer process from research to commercialization, thus creating value that is in tune with its mission. We are optimistic that the projects selected will result in collaborative advances of great importance in the oncology field", mentioned Renaldo Battista, Executive Director, Oncopole.
Four projects receiving substantial support
Following a competitive process and a thorough evaluation of requests from Quebec and the rest of Canada by an independent international peer review committee, four projects were selected. The winning teams will receive considerable financial support to continue their leading-edge oncology research work.
Post-transplant adoptive transfers of activated plasmacytoid dendritic cells to prevent acute leukemia relapse: toward the Phase I clinical trial[Team headed by Dr. Michel Duval, Investigator at the CHU Ste-Justine Research Centre]: Despite recent therapeutic advances, about 40% of children with acute leukemia refractory to chemotherapy still die from their disease. The only hope for cure for these children is stem cell transplantation, because the transplanted immune system is able to kill leukemia cells. The objective of the project is to develop a novel therapeutic approach to maximize the effect of the immune system against leukemia.
Development of first-in-class inhibitors of RAS GTPases[Team headed by Marc Therrien, Principal Investigator and Scientific Director at the Institute for Research in Immunology and Cancer of the Université de Montréal]: Activating mutations of RAS family proteins (H-, K- or NRAS) are collectively the most frequent causal event found in cancer of all types. Unfortunately, there are currently no therapeutic options to selectively target RAS activity. To make macrocycles (small molecules) a viable therapeutic option, we now need to improve their binding affinity to RAS and increase their ability to enter the cells. The objective of the project is to identify macrocycles that will block RAS activity in cancer cells in vitro and eventually, tumor growth in animal models.
Development of Electron Transport Chain (ETC) complex I inhibitors as poor outcome AML treatment [Team headed by Anne Marinier, Principal Investigator and Director of the Medicinal Chemistry Core Facility at the Institute for Research in Immunology and Cancer of the Université de Montréal]: Poor outcome acute myeloid leukemias represent an unmet medical need. Their recent studies show that a large portion of those leukemias, exhibiting a distinct genetic and metabolic identity, are sensitive to inhibition of electron transport chain complex I (ETC1) activity. The goal of this project is to develop a novel ETC1 inhibitor with improved potency and efficiency that will be ready for pre-clinical safety studies.
Chemical correction of mutated Keap1 generates highly selective chemosensitization by repairing a broken protein-protein interaction[Team headed by Dr. Gerald Batist, Director of the Segal Cancer Centre at the Jewish General Hospital]: Most tumors develop resistance to the various treatments available. Studies have shown that during treatments, not just one, but several mechanisms are activated, enabling tumors to resist various cancer therapies. The goal of this research project is to target a protein that is mutated in several cancers to eliminate the development of resistance to cancer drugs, which will increase the effectiveness of those drugs, leading to increasing the number of patients who recover from cancer.
About IRICoR
As a project maturation cluster in the field of drug discovery, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal. IRICoR's mandate is to accelerate the discovery, development, and commercialization of novel therapies in cancer, immunotherapy, and related fields. Since 2008, IRICoR has been successfully investing in and supporting selected cutting-edge projects in order to rapidly translate early-stage innovation into potential new therapies, through either co-development partnerships with the biopharmaceutical industry or the creation of spin-off companies. IRICoR seamlessly integrates its business-related expertise with access to industry-level drug discovery capabilities, providing selected academic and industry projects with access to its network of experts and cutting-edge infrastructure, including one of the largest academia-based medicinal chemistry groups in Canada. IRICoR's major funding sources include the Centres of Excellence for Commercialization and Research (CECR) program of the Canadian government, the Ministère de l'Économie, de la Science et de l'Innovation du Québec (MESI), and collaborative partnerships with the biopharmaceutical industry. For more information about IRICoR: iricor.ca.
About the Oncopole
The Oncopole is a Quebec hub for research, development and investment to accelerate the fight against cancer. Created in February of 2017, it is the product of a unique co-creation process led by the Fonds de recherche du Québec - Santé (FRQS) and made possible by an initial $15M investment from Merck Canada. The Oncopole's mission is to act as a catalyst leveraging actions made by the key players in Quebec's oncology and innovation research ecosystem. As a result, it aims to position the province as a leader in the field. Its priorities of action, namely research, entrepreneurship, commercialization and integration of innovation, as well as clinical relevance, are orchestrated in order to foster the mobilization of stakeholders, the discovery of innovative approaches to fight cancer and, ultimately, a positive impact for the benefit of patients. For more information, go to: oncopole.ca.
SOURCE IRICOR
$10M awarded to IRIC for the development of new cancer-fighting drugs and immunotherapies
MONTREAL, June 4, 2019 /CNW Telbec/ - The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal (UdeM) has been awarded a 10-million dollar grant from the government of Quebec's Fonds d'accélération des collaborations en santé (FACS), to develop new cancer-fighting drugs in collaboration with biopharmaceutical company Bristol-Myers Squibb and collaborators from seven academic research centres from Quebec and abroad. This major announcement was made today by Mr. Pierre Fitzgibbon, Minister of Economy and Innovation, on the occasion of the opening of the Quebec Pavilion at the BIO International Convention, held in Philadelphia June 3-6, 2019.
Financial support that provides hope
Entrusted with transforming, whenever possible, academic research into therapeutic solutions that will benefit patients, IRIC has joined with industry partners to pursue, over the next four years, a series of projects aimed at turning research efforts into therapeutic solutions that are accessible to patients. The program developed with Bristol-Myers Squibb is built on a portfolio of four oncology and cardiovascular disease projects based on innovative drug discovery concepts. They include developing drugs to reduce the side effects of treatments, using the immune system to vanquish cancer and the advancement of precision therapy to increase the effectiveness of the treatments offered.
"This great news once again confirms IRIC's vision and the relevance of our drug development model. It is recognition of the results stemming from the cutting-edge discoveries, technologies, and know-how of our institute's Investigators. It also perfectly illustrates the key role that fundamental research plays in making therapeutic solutions accessible for the benefit of patients", said Michel Bouvier, Project Director, CEO and Principal Investigator at IRIC.
By presenting cancer, immunotherapy and drug discovery research projects in collaboration with the biopharmaceutical community and seven Quebec academic research centres, IRIC fully met the objectives set by the FACS aimed at fostering collaborations between the players involved in the life sciences ecosystem. Among them, Michel Bouvier, Anne Marinier, Dr. Guy Sauvageau, Sylvain Meloche, Investigators at IRIC, Dr. Marc Bilodeau, Investigator at the CRCHUM, Dr. Frédéric Barabé, Investigator at the Centre de recherche du CHUL, Yoshua Bengio, founder of MILA, Dr. Nada Jabado, Investigator at the McGill University Health Centre, Morag Park, Investigator at the Rosalind and Morris Goodman Cancer Research Centre of McGill University and Richard Leduc, Investigator at the Centre de recherche du CHUS.
Through this initiative, the government of Quebec is banking on their individual strengths to bolster research excellence and ensure the international acclaim of Quebec as an innovative province in the field of life sciences.
"Implementing a program of collaboration between the public and private sector creates synergies that the health sector, and later the patients, will benefit from. We are delighted about this initiative", pointed out Robert Tessier, Chairman of the Board of the Caisse de dépôt et placement du Québec and Chairman of the Board, IRIC.
"It gives me great pleasure to underline this invaluable support that will enhance the excellence of the Quebec research network and that commends the efforts made on a daily basis by IRIC to find solutions to the scourge that now affects one in two Canadians", said Marie-Josée Hébert, Vice-Rector of Research, Discovery, Creation and Innovation at the Université de Montréal.
Through the Fonds d'accélération des collaborations en santé, the government of Quebec is making a long-term investment and reasserting its eagerness to support the cycle from academic research to drug discovery. It also underscores its desire to highlight research infrastructures and thereby guarantee the efficacy of the healthcare system and maximize the economic spinoffs for Quebec and the field of health sciences.
About the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal
An ultra-modern research hub and training centre located in the heart of the Université de Montréal, the Institute for Research in Immunology and Cancer of the Université de Montréal was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. The IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information: iric.ca
SOURCE Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal
Spectrum Therapeutics provides update on its global clinical research program and unveils pharmacovigilance program
SMITHS FALLS, ON, June 5, 2019 /CNW/ - Spectrum Therapeutics ("Spectrum"), the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (the "Company" or "Canopy Growth") is pleased to share an update on its efforts to develop and commercialize validated cannabis medicines through clinical trials. Demand for cannabinoid-based medicines is emerging around the world. With a highly experienced scientific team and the resources needed to conduct robust clinical trials, Spectrum Therapeutics is pursuing research to introduce products for the therapeutic areas of pain, mood and sleep and to gain access to new markets independent of medical cannabis laws.
CLINICAL RESEARCH Spectrum Therapeutics is focused over the next 24 months to further the science of cannabinoids and provide evidence by way of clinical trials on what conditions medical cannabis can treat. This research includes product design and ingredient selection, formulation, and safety and efficacy testing towards the development of standardized cannabis drug formulations and dose delivery systems. Research activity is occurring in two main areas: registration trials and exploratory studies.
Registration trials begin with phase I studies of cannabinoid products covering a spectrum of proprietary THC and CBD ratios. These initial trials provide critical dosing and safety data to inform subsequent phase II trials. Spectrum Therapeutics is pleased to announce that two phase I trials have already been completed, one each in Canada and Chile.
Exploratory "proof of concept" studies use a range of Spectrum products and design methodologies to explore different dose responses, and safety and efficacy signals for target conditions. Those that show promising results will be added to the registration trial pipeline and their initial findings will allow for optimal phase II trial design. The first proof of concept phase IIb "in human" clinical trial previously announced by the Company, to evaluate the use of medical cannabis for treating insomnia, is in progress in partnership with Drs. Julie Carrier and Alex Desautels at the Université de Montréal. It is expected to be completed by calendar Q2 2020 with results announced by calendar Q3 2020.
Other proof of concept studies are currently underway in partnership with researchers including Dr. Bernard Le Foll at the Centre for Addiction and Mental Health, Dr. Mary-Ann Fitzcharles at McGill University, and Dr. Angela Genge at the Montreal Neurological Institute. Over twenty conditions are being examined across these studies, including pain, sleep, and mood/anxiety disorders. Spectrum Therapeutics is also exploring areas such as neurodegenerative disorders in addition to the previously announced research partnership with NEEKA Health Canada and the NHL Alumni Association which is examining the efficacy of CBD-based therapies as part of a treatment for concussion symptoms. This clinical trial is expected to register its first patients by October 2019 with preliminary results by July 2020.
Recently acquired C3 Cannabinoid Compound Company ("C3") is currently progressing a clinical trial for the use of dronabinol to treat spasticity due to multiple sclerosis. Additionally, research on the potential of medical cannabis to treat cancer-related pain is also in the works with Beckley Canopy Therapeutics, a partnership established between U.K. drug research institute, The Beckley Foundation and Canopy Growth. Patient registrations for this trial are expected in September 2019.
To support its research program, Spectrum Therapeutics is pleased to announce the appointment of Dr. Marcel Bonn-Miller as Global Clinical Scientific Director. He brings to the team 18 years of experience researching cannabinoids and their various effects, has received funding for 27 research grants, and has led or contributed to 19 clinical trials. His work has been featured in 139 academic publications and 161 conference presentations, and he also serves on the editorial boards of five academic journals. Dr. Bonn-Miller previously worked as Director of Cannabinoid Research for Zynerba Pharmaceuticals, a leading transdermal cannabinoid pharmaceutical company. He is also an adjunct Assistant Professor at the University of Pennsylvania Perelman School of Medicine, known for his work examining the potential of cannabis in treating post-traumatic stress disorder.
Dr. Bonn-Miller will be supported by Hunter Land and Drs. Ryan Lanier and Erica Peters as Associate Directors. Land was instrumental in bringing the first cannabis-derived CBD medicine developed for patients with treatment-resistant forms of epilepsy, including Dravet and Lennox-Gastaut syndromes, to FDA approval. Dr. Peters was the lead clinical cannabis scientist for four years at Battelle, the world's largest non-profit research and development organization, and Dr. Lanier worked for Analgesic Solutions where he consulted on the development of pain medications for FDA approval.
PHARMACOVIGILANCE
In the interest of patient safety and good clinical practice, Spectrum Therapeutics is pleased to announce the implementation of a unique global pharmacovigilance program to capture and document adverse events reported from the worldwide use of its medical cannabis products in addition to the Company's Canadian recreational cannabis brands including Tweed and DNA Genetics, and its CBD product offerings.
Pharmacovigilance, also known as drug safety, is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects from the use of pharmaceutical products. While Spectrum Therapeutics and Canopy Growth were already reporting any adverse reactions to its cannabis products as per Health Canada regulations, the launch of this global pharmacovigilance program ensures that all employees are trained on how to identify and report adverse events. The Company's internal Pharmacovigilance team is responsible for analyzing and entering events into a global safety database compliant with regional regulatory requirements.
A global independent safety monitoring board chaired by Professor Yola Moride at the Université de Montréal will periodically review adverse event summaries and advise the Spectrum Therapeutics scientific team regarding product safety and clinical trial design.
"We believe that this strategic approach to global clinical research, in collaboration with outstanding investigators and institutions, and supported by our first-rate team of scientists, will generate innovative products for a number of indications with significant unmet needs," commented Dr. Mark Ware, Chief Medical Officer, Canopy Growth. "We are also pleased to announce the launch of our global pharmacovigilance program whereby every one of our 3000+ staff worldwide are trained in reporting adverse events. It's an important step towards establishing drug safety and will advance our efforts to provide patients with accepted, clinically validated cannabis medicines while transparently demonstrating the relative risks of cannabis."
Here's to (Clinically Validated) Future Growth.
About Canopy Growth Corporation Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through the Company's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents.
The Company's medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.
The Company operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.
From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.4 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com
Notice Regarding Forward Looking Statements This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include "expected to be completed by Q2 2020 with results announced by Q3 2020", and "those that show promising results will be added to the registration trial pipeline". Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including clinical trial results, product supply, and such risks contained in the Company's annual information form dated June 27, 2018 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
SOURCE Spectrum Therapeutics
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
